• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
USA China flag
Biotech

How RA Capital is offering ‘Chinese clinical expertise in a box’

Rather than leave the work of developing relationships in China to individual companies, the firm launched an initiative to scale the process.
Will Maddox Jun 5, 2026 8:19am
FDA

At CNPV hearing, industry support meets ‘concern’ from experts

Jun 5, 2026 5:00am
Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation
EULAR London 2026

Affibody gets izokibep ‘back on track’ after Acelyrin rejection

Jun 5, 2026 10:42am
x

Fierce Biotech Layoff Tracker 2026: Fulcrum, Novartis & more

Jun 5, 2026 9:45am
Illustration for Fierces Chutes  Ladders feature showing a blue city skyline with executives making career moves o

AstraZeneca adds FDA cell and gene veteran—Chutes & Ladders

Jun 5, 2026 8:30am
More News

Autobahn races toward ph. 3 after midstage bipolar depression win

Jun 4, 2026 11:31am

A divisive bill seeks to limit biotech investment in China

Jun 4, 2026 10:54am

Parabilis preps $413M IPO to fuel desmoid tumor drug into ph. 3

Jun 4, 2026 10:02am

Cabaletta's autoimmune CAR-T strategy is built on 'durability'

Jun 4, 2026 8:26am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings